Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Short-term Investments (2024 - 2025)

Prelude Therapeutics' Short-term Investments history spans 2 years, with the latest figure at $68.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 43.9% year-over-year to $68.0 million; the TTM value through Dec 2025 reached $68.0 million, down 43.9%, while the annual FY2025 figure was $68.0 million, 43.9% down from the prior year.
  • Short-term Investments for Q4 2025 was $68.0 million at Prelude Therapeutics, up from $7.4 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $177.2 million in Q1 2024 and bottomed at $7.4 million in Q3 2025.